Selective Recruitment of Presynaptic and Postsynaptic Forms of mGluR-LTD.
CA1
DHPG
hippocampus
long-term depression (LTD)
metabotropic glutamate (mGlu) receptor
Journal
Frontiers in synaptic neuroscience
ISSN: 1663-3563
Titre abrégé: Front Synaptic Neurosci
Pays: Switzerland
ID NLM: 101548972
Informations de publication
Date de publication:
2022
2022
Historique:
received:
18
01
2022
accepted:
20
04
2022
entrez:
26
5
2022
pubmed:
27
5
2022
medline:
27
5
2022
Statut:
epublish
Résumé
In area CA1 of the hippocampus, long-term depression (LTD) can be induced by activating group I metabotropic glutamate receptors (mGluRs), with the selective agonist DHPG. There is evidence that mGluR-LTD can be expressed by either a decrease in the probability of neurotransmitter release [P(r)] or by a change in postsynaptic AMPA receptor number. However, what determines the locus of expression is unknown. We investigated the expression mechanisms of mGluR-LTD using either a low (30 μM) or a high (100 μM) concentration of (RS)-DHPG. We found that 30 μM DHPG generated presynaptic LTD that required the co-activation of NMDA receptors, whereas 100 μM DHPG resulted in postsynaptic LTD that was independent of the activation of NMDA receptors. We found that both forms of LTD occur at the same synapses and that these may constitute the population with the lowest basal P(r). Our results reveal an unexpected complexity to mGluR-mediated synaptic plasticity in the hippocampus.
Identifiants
pubmed: 35615440
doi: 10.3389/fnsyn.2022.857675
pmc: PMC9126322
doi:
Types de publication
Journal Article
Langues
eng
Pagination
857675Informations de copyright
Copyright © 2022 Sanderson, Ralph, Amici, Ng, Kaang, Zhuo, Kim, Georgiou and Collingridge.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Neurosci. 2010 Jan 13;30(2):694-702
pubmed: 20071534
PLoS One. 2013 Aug 09;8(8):e71155
pubmed: 23951097
Neuron. 1997 Apr;18(4):599-612
pubmed: 9136769
J Neurosci. 2004 Jul 14;24(28):6352-61
pubmed: 15254091
Cell Mol Neurobiol. 2003 Apr;23(2):187-203
pubmed: 12735631
Neuron. 2010 Feb 25;65(4):445-59
pubmed: 20188650
Nature. 2011 Nov 23;480(7375):63-8
pubmed: 22113615
Nat Neurosci. 2011 Mar;14(3):338-44
pubmed: 21297630
Neuropharmacology. 2001 Nov;41(6):664-71
pubmed: 11640920
J Physiol. 2003 Jan 15;546(Pt 2):455-60
pubmed: 12527731
J Neurosci. 2010 Nov 17;30(46):15616-27
pubmed: 21084617
J Neurosci. 2011 Aug 24;31(34):12129-38
pubmed: 21865455
Annu Rev Pharmacol Toxicol. 1997;37:205-37
pubmed: 9131252
Neuron. 2011 Oct 20;72(2):300-15
pubmed: 22017989
J Neurophysiol. 2006 Apr;95(4):2427-38
pubmed: 16421200
J Neurosci Methods. 2007 May 15;162(1-2):346-56
pubmed: 17306885
Neuroscience. 1996 Nov;75(2):339-44
pubmed: 8931000
Science. 2017 Feb 3;355(6324):511-515
pubmed: 28154077
Neurobiol Dis. 2012 Mar;45(3):1101-10
pubmed: 22198573
Neurosci Lett. 1996 Jan 26;203(3):211-3
pubmed: 8742030
Science. 2017 Feb 3;355(6324):507-510
pubmed: 28154076
Neuron. 2017 Nov 15;96(4):839-855.e5
pubmed: 29033205
Nat Neurosci. 2001 Nov;4(11):1079-85
pubmed: 11687813
J Neurosci. 2005 Mar 16;25(11):2992-3001
pubmed: 15772359
Neuropharmacology. 2021 Jun 1;190:108426
pubmed: 33279506
J Neurosci Methods. 2012 Jun 15;207(2):148-60
pubmed: 22524994
Hippocampus. 2013 Feb;23(2):129-38
pubmed: 22996287
J Neurophysiol. 2002 Mar;87(3):1395-403
pubmed: 11877514
Mol Psychiatry. 2021 Sep;26(9):4652-4669
pubmed: 32606374
Biol Psychiatry. 2012 Dec 1;72(11):924-33
pubmed: 22817866
Nat Neurosci. 1999 Jul;2(7):618-24
pubmed: 10409387
Neuropharmacology. 1997 Nov-Dec;36(11-12):1517-32
pubmed: 9517422
Cell Rep. 2021 Jan 26;34(4):108664
pubmed: 33503425
Science. 2007 Jul 27;317(5837):530-3
pubmed: 17656725
Trends Neurosci. 2004 Jul;27(7):370-7
pubmed: 15219735
J Neurosci. 2006 Mar 1;26(9):2544-54
pubmed: 16510732
Nat Rev Neurosci. 2010 Jul;11(7):459-73
pubmed: 20559335
J Neurophysiol. 2007 Nov;98(5):2729-36
pubmed: 17898145
Front Neural Circuits. 2020 Apr 02;14:9
pubmed: 32308573
Eur J Neurosci. 2008 Mar;27(6):1345-52
pubmed: 18364018
Neuron. 2003 Aug 14;39(4):641-54
pubmed: 12925278
Eur J Neurosci. 2003 Aug;18(4):1017-20
pubmed: 12925027
J Neurosci. 2006 May 31;26(22):6089-95
pubmed: 16738253
Nat Commun. 2014 Aug 19;5:4701
pubmed: 25134715
J Physiol. 2001 Dec 1;537(Pt 2):421-30
pubmed: 11731575
J Neurosci. 2005 Jan 26;25(4):799-807
pubmed: 15673659
Neuropharmacology. 2001 Nov;41(6):693-9
pubmed: 11640923
Mol Brain. 2011 Jul 27;4:30
pubmed: 21794146
Nat Neurosci. 2014 Aug;17(8):1073-82
pubmed: 24974795
Cell Rep. 2018 Dec 26;25(13):3631-3646.e3
pubmed: 30590038
Brain Neurosci Adv. 2017 Jan;1(1):
pubmed: 28413831
Neuron. 2006 Dec 7;52(5):831-43
pubmed: 17145504
J Physiol. 2008 May 15;586(10):2499-510
pubmed: 18356198
Neuropharmacology. 1999 Oct;38(10):1577-83
pubmed: 10530819